Stocks that traded heavily or had substantial price changes on Tuesday: UnitedHealth Group, Morgan Stanley rise; PNC Financial, Live Nation fall
Intra-Cellular (ITCI) first-quarter earnings and revenues beat estimates. The company reiterates its previously issued guidance for 2023.
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 26.98% and 3.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular (ITCI) is witnessing growth aided by its sole-marketed drug, Caplyta. However, the lack of other promising candidates in the pipeline is concerning.
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.